Cargando…
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
BACKGROUND: CRE is an urgent threats to public health with a high mortality estimated at >30–50%. Until recently, polymyxin-based antibiotics were the only available options. However, a new therapeutic option has become available: ceftazidime-avibactam. We sought to describe outcomes from these i...
Autores principales: | Rahmati, Elham, Blodget, Emily, She, Rosemary C, Abbott, Jennifer Cupo, Bonomo, Robert A, Spellberg, Brad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632115/ http://dx.doi.org/10.1093/ofid/ofx163.644 |
Ejemplares similares
-
621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates
por: Belal, Maymonah, et al.
Publicado: (2019) -
2262. Ceftazidime–Avibactam vs. Polymyxin B in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
por: John, Jamie, et al.
Publicado: (2019) -
Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae
por: Alraddadi, Basem M., et al.
Publicado: (2019) -
1885. Cost-Effectiveness of Ceftazidime–Avibactam Compared With Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia
por: Sfeir, Maroun, et al.
Publicado: (2018) -
1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae
por: Satlin, Michael J, et al.
Publicado: (2019)